Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis

Sumona Datta, Keren Alvarado, Robert H. Gilman, Teresa Valencia, Christian Aparicio, Eric S. Ramos, Rosario Montoya, Carlton A. Evans

Research output: Contribution to journalArticle

Abstract

Background Assessing Mycobacterium tuberculosis (TB) viability by fluorescein diacetate (FDA) microscopy can predict TB culture results, treatment response and infectiousness. However, diverse methods have been published. We aimed to optimise FDA microscopy, minimising sputum processing, biohazard and complexity for use in resource-constrained settings. Methods and results Optimization: Patients with smear-positive pulmonary TB before treatment and healthy control participants provided sputa. These were divided into equal aliquots that were tested directly or after NaOH centrifuge-decontamination. Each aliquot was cultured and used to prepare slides (n = 80). FDA microscopy used: 1 or 3 drops of sputum; with/out acid-alcohol wash; with/out phenol sterilization; with 0/30/60 seconds KMnO4 quenching. Control samples all had negative culture and microscopy results. FDA microscopy had higher sensitivity when performed directly (without centrifuge-decontamination) on 1 drop of sputum (P<0.001), because 3 drops obscured microscopy. Acid-alcohol wash and KMnO4 quenching made bacilli easier to identity (P = 0.005). Phenol sterilization did not impair microscopy (P>0.1). Validation: The 2 protocols that performed best in the optimization experiments were reassessed operationally by comparing duplicate slides (n = 412) stained with KMnO4 quenching for 30 versus 60 seconds. FDA microscopy results were similar (P = 0.4) and highly reproducible, with 97% of counts agreeing within +/-1 logarithm. Storage: Smear microscopy slides and aliquots of the sputum from which they were made were stored for 4 weeks. Twice-weekly, paired slides (n = 80) were stained with freshly prepared versus stored FDA and read quantitatively. Storing sputum, microscopy slides or FDA solution at 4C or room temperature had no effect on FDA microscopy results (all P>0.2). Cost: Material costs for each slide tested by FDA microscopy using reagents purchased locally were USD $0.05 and required the same equipment, time and skills as auramine acid-fast microscopy. Conclusions We recommend a simple, bio-secure protocol for FDA microscopy that provides sensitive and repeatable results without requiring centrifugation.

Original languageEnglish (US)
Article numbere0214131
JournalPloS one
Volume14
Issue number4
DOIs
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis'. Together they form a unique fingerprint.

  • Cite this

    Datta, S., Alvarado, K., Gilman, R. H., Valencia, T., Aparicio, C., Ramos, E. S., Montoya, R., & Evans, C. A. (2019). Optimising fluorescein diacetate sputum smear microscopy for assessing patients with pulmonary tuberculosis. PloS one, 14(4), [e0214131]. https://doi.org/10.1371/journal.pone.0214131